Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision

@inproceedings{Donada2013ManagementOS,
  title={Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision},
  author={Marisa Donada and Serena Bonin and Renzo Barbazza and Daniel Pettirosso and Giorgio Stanta},
  booktitle={BMC gastroenterology},
  year={2013}
}
BACKGROUND There is uncertainty on the benefit of adjuvant chemotherapy in patients with stage II colorectal cancers. The aim of this study is to investigate the combined role of clinical, pathological and molecular parameters to identify those stage II patients who better benefit from adjuvant therapy. METHODS We examined 120 stage II colon cancer patients. Of these, 60 patients received adjuvant 5-FU chemotherapy after surgery and the other 60 did not receive therapy. Immunohistochemical… CONTINUE READING